RNS Number : 2682C Renalytix AI PLC 16 October 2020 Renalytix AI plc (" RenalytixAI " or the " Company ") Notice of results Analyst and Investor presentations RenalytixAI To Announce Financial Results for Full Year Ended June 30, 2020 and Provide Corporate Update NEW YORK , October 16,
RNS Number : 9631B Renalytix AI PLC 13 October 2020 Not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or within the United States , Australia , Canada , Hong Kong , Japan , New Zealand , the Republic of South Africa or any other jurisdiction where
RNS Number : 6495Z Renalytix AI PLC 22 September 2020 This announcement contains inside information Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Receives California Commercial Laboratory Certification RenalytixAI is now currently licensed to provide KidneyIntelX testing
RNS Number : 4123Z Renalytix AI PLC 18 September 2020 This announcement contains inside information Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System NEW YORK , September 18, 2020 - Renalytix AI
RNS Number : 7366X Renalytix AI PLC 02 September 2020 Renalytix AI plc ("RenalytixAI", the "Company") Grant of Purchase Rights under the 2020 Employee Share Purchase Plan and Verici update NEW YORK , September 2, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX) announces that on 28
RNS Number : 1457X Renalytix AI PLC 26 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX NEW YORK , August 26, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX), an artificial intelligence -enabled in vitro
RNS Number : 7551W Renalytix AI PLC 21 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease Parties to adopt multi-phase approach to develop precision medicine strategies to optimize
RNS Number : 8477U Renalytix AI PLC 03 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study
RNS Number : 8003U Renalytix AI PLC 31 July 2020 Renalytix AI plc (the "Company") Total Voting Rights For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2020 , the Company's issued and fully paid share capital
RNS Number : 0885U Renalytix AI PLC 27 July 2020 Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction Renalytix AI plc Over allotment option exercise
